5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.63▲ | 0.63▲ | 0.63▲ | 0.61▲ | 0.61▲ |
MA10 | 0.61▲ | 0.61▲ | 0.61▲ | 0.60▲ | 0.66▼ |
MA20 | 0.60▲ | 0.60▲ | 0.60▲ | 0.60▲ | 0.80▼ |
MA50 | 0.59▲ | 0.59▲ | 0.59▲ | 0.68▼ | 1.13▼ |
MA100 | 0.62▲ | 0.63▲ | 0.65▼ | 0.81▼ | 1.66▼ |
MA200 | 0.71▼ | 0.75▼ | 0.78▼ | 1.02▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.007▲ | 0.007▲ | 0.008▲ | 0.012▲ | 0.003▲ |
RSI | 62.142▲ | 61.155▲ | 60.227▲ | 52.651▲ | 38.646▼ |
STOCH | 96.859▲ | 97.790▲ | 97.790▲ | 58.228 | 19.640▼ |
WILL %R | -1.524▲ | -1.524▲ | -1.524▲ | 0.000▲ | -73.263 |
CCI | 129.174▲ | 131.063▲ | 130.735▲ | 199.149▲ | -78.806 |
Tuesday, April 29, 2025 06:05 AM
Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells TNX-1700 is in preclinical development ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 0.635 | 0.65 | 0.61 | 0.65 | 14,823 |
30/04/25 | 0.609 | 0.6199 | 0.575 | 0.6199 | 12,163 |
29/04/25 | 0.5941 | 0.605 | 0.5777 | 0.605 | 24,737 |
28/04/25 | 0.6104 | 0.6193 | 0.56 | 0.6031 | 48,670 |
25/04/25 | 0.57 | 0.603 | 0.56 | 0.5884 | 20,900 |
24/04/25 | 0.57 | 0.63 | 0.56 | 0.56 | 7,400 |
23/04/25 | 0.602 | 0.631 | 0.563 | 0.5947 | 30,411 |
22/04/25 | 0.56 | 0.6305 | 0.5569 | 0.6088 | 35,676 |
21/04/25 | 0.61 | 0.638 | 0.567 | 0.567 | 32,453 |
17/04/25 | 0.6141 | 0.64 | 0.578 | 0.635 | 109,164 |
|
|
||||
|
|
||||
|
|